Janssen COVID-19 Vaccine (Ad26.COV2-S (recombinant))

• On 19 April 2021, the Food and Drug Administration (FDA) issued authorization (amended on 28 March 2022) granting Johnson & Johnson (Philippines), Inc. the emergency use approval of Janssen COVID-19 Vaccine.

Fact Sheet for Healthcare Providers Administering the Vaccine
                             English     Tagalog

                           Fact Sheet for Recipients and Caregivers
                             English     Tagalog

• For more information on reporting side effects, click here.